Successful treatment of acrodermatitis continua of Hallopeau by the tumour necrosis factor-alpha inhibitor infliximab (Remicade).
Mang
R
R
Ruzicka
T
T
Stege
H
H
D000169:Acrodermatitis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000627:therapeutic use*; D047889:Receptors, Tumor Necrosis Factor, Type II; D016896:Treatment Outcome; D053319:Tumor Necrosis Factor Decoy Receptors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab